Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4000
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Sucralfate (Tablet)
|
| dailymed-instance:dosage |
Active Duodenal Ulcer: The recommended adult oral dosage for duodenal ulcer is 1 g four times per day
on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day. Elderly: In general, dose selection for an elderly patient should be cautious, usually starting
at the low end of the dosing range, reflecting the greater frequency of decreased hepatic,
renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS Geriatric Use
)
|
| dailymed-instance:clinicalP... |
Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are
excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent: These observations suggest that sucralfate's antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer
site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g
dose of sucralfate.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:supply |
Sucralfate 1-g tablets, USP are supplied in bottles of 100 and 500.
White, scored, oblong tablets are embossed with "N" and "S1". Bottles of 100 NDC 29033-003-01 Bottles of 500 NDC 29033-003-05 Store at 20��-25��C (68��-77��F) (See USP Controlled Room Temperature). Rx Only Manufactured and Distributed by: Nostrum Laboratories, Inc.Kansas City, MO 64120 Printed in USAOct 2007
|
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:possibleD... |
diseasome-diseases:1130,
diseasome-diseases:1358,
diseasome-diseases:1359,
diseasome-diseases:1427,
diseasome-diseases:1436,
diseasome-diseases:2198,
diseasome-diseases:2202,
diseasome-diseases:2203,
diseasome-diseases:2204,
diseasome-diseases:2205,
diseasome-diseases:2730,
diseasome-diseases:338,
diseasome-diseases:342,
diseasome-diseases:4046,
diseasome-diseases:4047,
diseasome-diseases:46,
diseasome-diseases:576,
diseasome-diseases:79,
diseasome-diseases:81
|
| dailymed-instance:genericMe... |
sucralfate
|
| dailymed-instance:fullName |
Sucralfate (Tablet)
|
| dailymed-instance:adverseRe... |
Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over
2700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence,
dry mouth Dermatological: pruritus, rash Nervous System: dizziness, insomnia, sleepiness, vertigo Other: back pain, headache Postmarketing reports of hypersensitivity reactions, including urticaria (hives), angioedema, respiratory difficulty, rhinitis, laryngospasm, and facial swelling have been reported in patients receiving sucralfate tablets. Similar events were reported with sucralfate suspension. However, a causal relationship has not been established. Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary
and cerebral emboli. Sucralfate is not intended for intravenous administration.
|
| dailymed-instance:indicatio... |
Sucralfate tablets, USP are indicated in:
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Sucralfate
|